SETD2 and melanoma: In addition to SETD2 mutations, we found that the use of single-agent CTLA4 contributed less to the incidence of recurrence, followed by combination, and finally single-agent PD-1/PD-L1, which shows the importance of CTLA4 in the treatment of melanoma, of course, the clinical application is relatively limited compared with PD-1/PD-l1 which is mainly related to its more serious treatment-related adverse reactions [43–45].